Top 10 Cited Psychedelic Papers

This small ketamine trial helped launch the modern era of rapid-acting antidepressant research. By showing antidepressant effects within days in people with depression, it opened a line of work that later expanded across thousands of ketamine and esketamine studies.

Griffiths and colleagues reintroduced rigorous psilocybin research in healthy volunteers. The study is important because it showed that a supported high-dose session could occasion personally meaningful mystical-type experiences with positive effects that participants still valued later.

This cancer-distress trial connected a single high-dose psilocybin session with sustained reductions in depression and anxiety. It also linked outcomes to mystical-type experience, shaping later debates about whether subjective experience is part of the therapeutic mechanism.

Nichols gave the field a broad pharmacological map of classical hallucinogens before the current research wave accelerated. The review remains useful because it connects receptor pharmacology, brain systems, subjective effects, and early therapeutic possibilities in one reference point.

This ketamine-metabolite paper shifted attention from NMDA receptor blockade alone to downstream mechanisms that might preserve antidepressant effects with fewer acute side effects. It is a key mechanistic bridge between ketamine research and new drug-development strategies.

This open-label feasibility study was the first modern clinical test of psilocybin with psychological support for treatment-resistant depression. Its small sample and lack of control group limited interpretation, but it showed enough promise to justify larger controlled trials.

Ross and colleagues tested psilocybin-assisted psychotherapy for anxiety and depression in people with life-threatening cancer. The trial matters because it paired rapid symptom relief with improvements in demoralisation, spiritual wellbeing, and attitudes toward death.

Grob and colleagues ran one of the first modern placebo-controlled psilocybin trials in patients with advanced cancer. The study was small, but it reopened clinical work on psilocybin for end-of-life anxiety and helped set the stage for the larger 2016 trials.

This two-site trial strengthened the case for ketamine in treatment-resistant depression by comparing it with an active placebo. It is notable because it showed rapid antidepressant effects in a more rigorous design than many earlier ketamine studies.

This fMRI study helped define the early neuroscience of the psilocybin state. By showing reduced activity and connectivity in key network hubs, it challenged simple ideas of psychedelics as globally excitatory and shaped later work on brain networks and unconstrained cognition.